PP_1170x120_10-25-21

Silvidiol

Former NBA champion John Salley joins Leading Edge Pharms

Former NBA champion John Salley joins Leading Edge Pharms

HENDERSON, Nev. – Leading Edge, a biotechnology company developing novel cannabinoid therapies and innovative delivery systems, announced Monday that former professional basketball player and cannabis advocate John Salley has been appointed as executive vice president of marketing, effective immediately. Salley will help Leading Edge market Cannavera, its lineup of CBD-based topical pain and inflammation solutions.

Leading Edge names Dr. Holsworth as CSO to head up clinical CBD research

Leading Edge names Dr. Holsworth as CSO to head up clinical CBD research

HENDERSON, Nev. – Leading Edge Pharms (LEP) a biotechnology company developing novel cannabinoid therapies and innovative delivery systems, announced Tuesday that Dr. Daniel Holsworth has been appointed chief science officer (CSO). Dr. Holsworth’s appointment signals LEP’s further commitment to providing clinically supported CBD-based solutions for topical pain relief and inflammatory skin conditions. “One of our

Study by Tioga Research supports efficacy of liposomal compound Silvidiol

Study by Tioga Research supports efficacy of liposomal compound Silvidiol

HENDERSON, Nev. — Leading Edge Pharms, (LEP) a biotechnology company developing novel cannabinoid therapies and innovative delivery systems, announced the results of a Tioga Research-led study, indicating that its proprietary cannabidiol-based (CBD) pain relief and anti-inflammatory agent, Silvidiol, effectively permeates the epidermis to reach somatic and neuropathic sensory receptors below the surface of the skin.